动脉粥状硬化药物市场－全球产业规模、份额、趋势、机会和预测：按诊断、治疗、给药途径、最终用户、地区和竞争格局划分，2021-2031年

全球动脉粥状硬化治疗市场预计将从 2025 年的 191.1 亿美元成长到 2031 年的 238.6 亿美元，预测期内复合年增长率为 3.77%。

这些药物的主要目的是透过控制血脂水平和预防血栓形成来抑制动脉斑块的积聚，从而预防心血管疾病的发生。全球心血管疾病负担日益加重以及人口老化（老年人罹患动脉粥状斑块的风险增加）是推动市场成长的主要因素。美国心臟协会的报告凸显了这一紧迫性，该报告预测，到2024年，心血管疾病将导致全球每年约1,991万人死亡。这项数据有力地显示了持续的药物介入和旨在稳定斑块的治疗方案的重要性。

然而，市场面临一个重大障碍：重磅药物的专利到期。随后，价格低廉的学名药上市，显着降低了现有品牌药物的市场份额和收入潜力。因此，药物研发人员面临越来越大的创新压力，但高昂的研发成本和严格的监管要求往往会延长下一代动脉粥状硬化治疗药物的商业化。

市场驱动因素

全球心血管疾病和高血脂症率的不断上升是动脉粥状硬化治疗市场的主要驱动力。随着久坐不动的生活方式和不良饮食习惯日益普遍，动脉斑块积聚和血脂异常的发生率也随之增加，导致需要药物治疗的患者群体庞大。这种日益加重的疾病负担推动了对降血脂疗法（例如他汀类药物和联合用药）的需求，以预防中风和心肌梗塞等严重后果。根据美国心臟协会 (AHA) 于 2024 年 1 月发布的《2024 年心臟病和中风统计更新》，2017 年至 2020 年间，美国约有 1.279 亿成年人患有某种形式的心血管疾病。如此高的盛行率促使医疗保健提供者积极开立处方药，从而确保了製药商稳定的收入来源。

同时，新型疗法的进步，尤其是PCSK9抑制剂，正在重塑市场格局。製药公司正大力投资研发，力求为无法耐受传统他汀类药物或需要进一步降低血脂的患者推出新一代生物製药和口服药物。例如，2024年7月，新阿姆斯特丹製药公司发表了其3期BROOKLYN临床试验的结果，显示新型CETP抑制剂obicetrapib在第84天时使低密度脂蛋白胆固醇水平较安慰剂对照组降低了36.3%。这些先进疗法的商业性成功也反映在财务表现上。根据安进公司于2024年10月公布的2024年第三季财务报告，PCSK9抑制剂Repata的销售额达到5.67亿美元，年增40%，显示创新技术透过满足高风险族群的需求来推动市场价值的重要性。

市场挑战

重磅疗法专利到期对全球动脉粥状硬化治疗市场的成长构成重大阻碍。随着关键抗血栓和降血脂药物的专利保护期结束，学名药价格远低于品牌药。这种转变将显着降低市场估值，因为专利药带来的高额利润将被学名药低利润、高销售量的经济模式所取代。因此，原厂药生产商面临收入快速下滑的困境，限制了整个产业的财务扩张，并减少了可用于高风险研发倡议的再投资资金。

这项财务挑战的规模庞大且可量化。 2024年，可及药品协会报告称，学名药在上年度为心臟病患者节省了1,181亿美元。这一数字有力地说明了品牌药产业的巨大价值流失。这种高性价比替代品的广泛应用抑制了市场的整体获利潜力，使得该产业难以维持其以往依赖成熟产品线的传统成长模式。

市场趋势

Glucagon-Like Peptide-1(GLP-1)促效剂在心血管疾病预防领域的应用拓展，代表着动脉粥状硬化治疗市场的变革性趋势。这些疗法最初核准用于体重管理和糖尿病治疗，如今正越来越多地被用于降低已确诊动脉粥状硬化性心血管疾病患者发生重大不利事件的风险。这项转变认识到全身代谢因素会加剧动脉斑块的不稳定性，并将治疗目标从单纯的血脂管理扩展到全面管理更广泛的代谢和发炎风险。为了支持这一转变，诺和诺德在其2024年3月的新闻稿「Wegovy核准在美国用于降低超重或肥胖患者的心血管风险」中宣布，临床试验表明，2.4毫克Semaglutide可使已知患有心血管疾病的超重或肥胖成人发生重大不利事件的风险降低20%。

同时，针对降低脂蛋白(a)水平的标靶治疗的研发正在填补精准医疗领域的一个重要空白。高水平的Lp(a)是一种遗传决定的风险因素，它独立于低密度脂蛋白胆固醇水平促进动脉粥样硬化，且通常对标准他汀类药物治疗无效。製药研发人员正在利用先进的小干扰RNA (SMRNA)技术来沉默负责产生这些动脉粥状硬化颗粒的基因，为心血管风险较高的患者带来了新的希望。为了支持这项疗法的有效性，Silence Therapeutics公司在2024年5月发布的题为「Silence Therapeutics公布Zelurasiran II期研究第36週的积极数据」的新闻稿中宣布，其在研药物Zelurasiran在最高两个剂量组的受试者中，于第36週时使脂蛋白位数(a)水平中降低了90%以上。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球动脉粥状硬化治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 透过诊断（踝臂指数、多普勒超音波、心臟超音波图、心电图、血液检查、其他）
  • 依治疗方法（药物治疗、手术、其他）
  • 依给药途径（口服、肠外、其他）
  • 按最终使用者（医院/诊所、门诊护理中心、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美动脉硬化药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

第七章 欧洲动脉硬化药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章 亚太地区动脉硬化治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章 中东和非洲动脉硬化治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美动脉硬化治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球动脉粥状硬化药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Merck & Co. Inc.
• Pfizer Inc.
• Eli Lilly and Co.
• Sanofi SA
• AstraZeneca Plc
• Bayer AG
• Regeneron Pharmaceuticals Inc.
• GSK Plc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Atherosclerosis Drugs Market is projected to expand from USD 19.11 Billion in 2025 to USD 23.86 Billion by 2031, registering a CAGR of 3.77% throughout the forecast period. These pharmaceutical agents are designed to reduce the accumulation of arterial plaque, principally by managing lipid concentrations and preventing thrombus formation to avert cardiovascular incidents. The market's growth is fundamentally underpinned by the mounting global burden of cardiovascular diseases alongside an aging population increasingly prone to arterial hardening. Highlighting this urgency, the American Heart Association reported in 2024 that cardiovascular diseases were responsible for approximately 19.91 million deaths worldwide each year, a statistic that emphasizes the critical need for sustained pharmacological interventions and therapeutic regimens aimed at plaque stabilization.

However, the market faces a substantial obstacle in the form of patent expirations for major blockbuster drugs. The subsequent introduction of affordable generic alternatives significantly diminishes the market share and revenue potential of established branded therapies. As a result, pharmaceutical developers are under mounting pressure to innovate, although the high costs of development and stringent regulatory requirements frequently prolong the timeline for bringing next-generation atherosclerosis treatments to commercial realization.

Market Driver

The escalating global incidence of cardiovascular diseases and hyperlipidemia acts as the primary engine driving the atherosclerosis drugs market. As sedentary lifestyles and suboptimal dietary habits become increasingly common, the frequency of arterial plaque buildup and lipid irregularities has risen, resulting in a vast patient population requiring pharmacological treatment. This growing disease burden necessitates a higher volume of lipid-lowering therapies, such as statins and combination drugs, to avert critical outcomes like strokes and myocardial infarctions. According to the American Heart Association's "2024 Heart Disease and Stroke Statistics Update" from January 2024, an estimated 127.9 million adults in the United States were affected by some form of cardiovascular disease between 2017 and 2020, a prevalence that compels healthcare providers to aggressively prescribe medications, ensuring steady revenue streams for manufacturers.

Concurrently, the market is being reshaped by advancements in novel therapeutics, particularly the robust development of PCSK9 inhibitors. Pharmaceutical entities are heavily investing in research and development to bring next-generation biologics and oral options to market for patients who cannot tolerate traditional statins or require further lipid reduction. For example, NewAmsterdam Pharma reported in July 2024 within their "Phase 3 BROOKLYN Clinical Trial Results" that the novel CETP inhibitor obicetrapib realized a 36.3% decrease in low-density lipoprotein cholesterol by day 84 relative to a placebo. The commercial success of such advanced treatments is reflected in financial performance; Amgen's "Third Quarter 2024 Financial Results" from October 2024 indicated that sales for the PCSK9 inhibitor Repatha rose by 40% year-over-year to reach $567 million, demonstrating how these innovations drive market value by meeting the needs of high-risk populations.

Market Challenge

The expiration of patents for key blockbuster therapies presents a formidable barrier to the financial growth of the Global Atherosclerosis Drugs Market. As exclusivity periods for major antithrombotic and lipid-regulating agents come to an end, the sector encounters a surge of generic competitors that are priced substantially lower than branded originals. This shift causes a marked decline in market valuation, as the significant revenues generated by exclusive proprietary drugs are supplanted by the low-margin, high-volume economics typical of generic formulations. Consequently, original manufacturers face rapid revenue erosion, which suppresses the sector's overall monetary expansion and limits the funds available for reinvesting into high-risk research initiatives.

The magnitude of this financial challenge is both significant and measurable. In 2024, the Association for Accessible Medicines reported that generic medications delivered $118.1 billion in savings for patients with heart disease over the previous year, a figure that effectively illustrates the massive value diverted from the branded pharmaceutical sector. This widespread uptake of cost-efficient alternatives curtails the overall revenue potential of the market, creating a landscape where the industry struggles to maintain historical growth trajectories that relied heavily on established product lines.

Market Trends

The expansion of labels for Glucagon-Like Peptide-1 agonists to include cardiovascular prevention marks a transformative trend within the atherosclerosis drugs market. Although initially approved for weight management and diabetes, these therapeutics are increasingly adopted to lower the risk of major adverse cardiovascular events in individuals with established atherosclerotic cardiovascular disease. This transition recognizes the systemic metabolic factors that aggravate arterial plaque instability, extending treatment goals beyond simple lipid management to encompass broader metabolic and inflammatory risks. Underscoring this shift, Novo Nordisk announced in a March 2024 press release titled "Wegovy approved in the US for cardiovascular risk reduction in people with overweight or obesity" that clinical trials showed semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% in overweight or obese adults with known cardiovascular disease.

In parallel, the creation of targeted therapies aimed at lowering Lipoprotein(a) is fulfilling a crucial unmet need in precision medicine. Elevated Lipoprotein(a) serves as a genetically determined risk factor that promotes atherosclerosis independently of low-density lipoprotein cholesterol levels and generally does not respond to standard statin treatments. Pharmaceutical developers are utilizing advanced small interfering RNA technologies to suppress the genes responsible for generating this atherogenic particle, providing new prospects for patients with high residual cardiovascular risk. Validating this approach, Silence Therapeutics revealed in May 2024, within the "Silence Therapeutics Announces Positive 36-Week Data from Phase 2 Study of Zerlasiran," that the investigational drug zerlasiran attained a median Lipoprotein(a) reduction of 90% or more at week 36 for participants in the top two dosage cohorts.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Novartis AG
• Merck & Co. Inc.
• Pfizer Inc.
• Eli Lilly and Co.
• Sanofi S.A.
• AstraZeneca Plc
• Bayer AG
• Regeneron Pharmaceuticals Inc.
• GSK Plc

Report Scope

In this report, the Global Atherosclerosis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Atherosclerosis Drugs Market, By Diagnosis

• Ankle-brachial Index
• Doppler Ultrasound
• Echocardiogram
• Electrocardiogram
• Blood Tests
• Others

Atherosclerosis Drugs Market, By Treatment

• Medication
• Surgery
• Others

Atherosclerosis Drugs Market, By Route of Administration

• Oral
• Parenteral
• Others

Atherosclerosis Drugs Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Atherosclerosis Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Atherosclerosis Drugs Market.

Available Customizations:

Global Atherosclerosis Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Atherosclerosis Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Diagnosis (Ankle-brachial Index, Doppler Ultrasound, Echocardiogram, Electrocardiogram, Blood Tests, Others)
  • 5.2.2. By Treatment (Medication, Surgery, Others)
  • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Atherosclerosis Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Diagnosis
  • 6.2.2. By Treatment
  • 6.2.3. By Route of Administration
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Atherosclerosis Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Diagnosis
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Atherosclerosis Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Diagnosis
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Atherosclerosis Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Diagnosis
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By End User

7. Europe Atherosclerosis Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Diagnosis
  • 7.2.2. By Treatment
  • 7.2.3. By Route of Administration
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Atherosclerosis Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Diagnosis
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By End User
  • 7.3.2. France Atherosclerosis Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Diagnosis
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Atherosclerosis Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Diagnosis
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Atherosclerosis Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Diagnosis
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Atherosclerosis Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Diagnosis
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By End User

8. Asia Pacific Atherosclerosis Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Diagnosis
  • 8.2.2. By Treatment
  • 8.2.3. By Route of Administration
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Atherosclerosis Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Diagnosis
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By End User
  • 8.3.2. India Atherosclerosis Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Diagnosis
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Atherosclerosis Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Diagnosis
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Atherosclerosis Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Diagnosis
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Atherosclerosis Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Diagnosis
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By End User

9. Middle East & Africa Atherosclerosis Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Diagnosis
  • 9.2.2. By Treatment
  • 9.2.3. By Route of Administration
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Atherosclerosis Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Diagnosis
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Atherosclerosis Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Diagnosis
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Atherosclerosis Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Diagnosis
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By End User

10. South America Atherosclerosis Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Diagnosis
  • 10.2.2. By Treatment
  • 10.2.3. By Route of Administration
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Atherosclerosis Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Diagnosis
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Atherosclerosis Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Diagnosis
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Atherosclerosis Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Diagnosis
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Atherosclerosis Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Merck & Co. Inc.
• 15.4. Pfizer Inc.
• 15.5. Eli Lilly and Co.
• 15.6. Sanofi S.A.
• 15.7. AstraZeneca Plc
• 15.8. Bayer AG
• 15.9. Regeneron Pharmaceuticals Inc.
• 15.10. GSK Plc

16. Strategic Recommendations

17. About Us & Disclaimer